Stock Research for ALPMY

ALPMY
Current Price

$14.3200


Latest Update: 2018-02-23 16:00:00

High
$ 14.3200
Low
$ 14.3200
Close
$ 14.3200
Volume
6421
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ALPMY Stock Chart & Research Data

The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMY Due diligence Resources & Stock Charts

The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMY Detailed Price Forecast - CNN Money CNN View ALPMY Detailed Summary - Google Finance
Yahoo View ALPMY Detailed Summary - Yahoo! Finance Zacks View ALPMY Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ALPMY Trends & Analysis - Trade-Ideas Barrons View ALPMY Major Holders - Barrons
NASDAQ View ALPMY Call Transcripts - NASDAQ Seeking View ALPMY Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMY Annual Report - CompanySpotlight.com OTC Report View ALPMY OTC Short Report - OTCShortReport.com
TradeKing View ALPMY Fundamentals - TradeKing Charts View ALPMY SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMY - The WSJ Morningstar View Performance/Total Return for ALPMY - Morningstar
MarketWatch View the Analyst Estimates for ALPMY - MarketWatch CNBC View the Earnings History for ALPMY - CNBC
StockMarketWatch View the ALPMY Earnings - StockMarketWatch MacroAxis View ALPMY Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMY Bullish Patterns - American Bulls Short Pains View ALPMY Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ALPMY Stock Mentions - StockTwits PennyStocks View ALPMY Stock Mentions - PennyStockTweets
Twitter View ALPMY Stock Mentions - Twitter Invest Hub View ALPMY Investment Forum News - Investor Hub
Yahoo View ALPMY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMY Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMY - SECform4.com Insider Cow View Insider Transactions for ALPMY - Insider Cow
CNBC View ALPMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMY - OTC Markets
Yahoo View Insider Transactions for ALPMY - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMY - NASDAQ


Stock Charts

FinViz View ALPMY Stock Insight & Charts - FinViz.com StockCharts View ALPMY Investment Charts - StockCharts.com
BarChart View ALPMY Stock Overview & Charts - BarChart Trading View View ALPMY User Generated Charts - Trading View


Latest Financial News for ALPMY

Astellas Acquires Universal Cells, Inc.
Posted on Tuesday February 13, 2018

TOKYO, Feb. 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell, "Universal Cells") today announced that Astellas has acquired Universal Cells. Astellas will gain Universal Cells' proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection.


Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Posted on Monday February 05, 2018

TOKYO and NEW YORK , Feb. 5, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503), President and CEO: Yoshihiko Hatanaka , "Astellas," and Pfizer Inc. (NYSE: PFE) announced today results from ...


Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium
Posted on Monday January 29, 2018

- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions - TOKYO , Jan. 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, ...


Astellas Completes Acquisition of Mitobridge, Inc.
Posted on Tuesday January 23, 2018

TOKYO, Jan. 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Mitobridge, Inc. ("Mitobridge"), and Mitobridge has become a wholly owned subsidiary of Astellas as of January 23, 2018 (U.S. Eastern Time). By exercising the option right to acquire Mitobridge, Astellas paid $225 million1 to acquire 100% of the equity in Mitobridge. In addition, Mitobridge shareholders will be eligible for additional payments from Astellas that total up to $225 million2 depending on the progress of various programs in clinical development.


Astellas Pharma buying Universal Cells for $102M in Seattle's third biotech ...
GeekWire - Feb 15, 2018
“We are thrilled to be able to leverage the full potential of our Universal Donor Cell technology by becoming an intrinsic part of Astellas' effort to fulfill the promises of regenerative medicine to treat diseases,” Claudia Mitchell, Universal Cells ...

Astellas acquires Universal Cells for up to $102.5M
Seeking Alpha - Feb 14, 2018
Astellas Pharma (OTCPK:ALPMF) has acquired Seattle, WA-based Universal Cells, Inc. and its Universal Donor Cell technology enabling the creation of cell therapy products that do not require human leukocyte antigen (HLA) matching which greatly reduces ...
Astellas Acquires Universal Cells, Inc. - PR Newswire (press release)
Astellas Buys Stem Cell Gene-Editing Firm Universal Cells for $102.5M - Xconomy

Global Overactive Bladder Market Report 2017-2027: Astellas Pharma Leads ...
PR Newswire (press release) - Feb 19, 2018
Majority of these therapies are being administered via the oral route, with the remainder being subcutaneous and intravesical formulations.
Global Overactive Bladder Treatment Market Growth 2018-2023: Pfizer, Allergan ... - People Exclusive

Astellas Pharma expands portfolio by acquiring Universal Cells
Life Sciences Intellectual Property Review - Feb 16, 2018
Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

Enter a stock symbol to view the stock details.